6) Chemical Therapeutics
Abstract
Focuses on therapeutic strategies to effectively minimize injuries resulting from exposure to CWAs. This effort involves the development of neuroprotectants, anticonvulsants, improved therapies for enzyme reactivation, and investigation of alternate pathways leading to treatment. This effort also includes discovery and development of therapeutic strategies to treat dermal, ocular and respiratory injuries of CWAs. Efforts in this area are designed to develop potential candidates that will ultimately be submitted for Food and Drug Administration (FDA) licensure or to identify previously licensed products for new uses in the treatment of chemical warfare casualties. This effort is being separated into four thrust areas starting in FY21: Chemical Reactive Ocular Wound and Dermal Therapeutics (CROWD), Enabling Science, Pharmaceutical Based Agents (PBA), and Reactivators of AChE as Therapeutics (ReACT).
Document Details
- Document Type
- Accomplishment
- Publication Date
- Oct 01, 2022
- Source ID
- 22493ed0b7619a2ccf235cd0033274de